FDA Inspection 1134749 — Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc. — FEI 3016603289

The FDA completed an inspection of Apellis Pharmaceuticals, Inc. on November 13, 2020 in Waltham, MA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
November 13, 2020
Fiscal Year
2021
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Waltham, MA (United States)

Additional Details

Sponsor, Contract Research Organization